

National Pharmaceutical Pricing Authority

Subject: Minutes of the 66th meeting of the Multidisciplinary Committee of Experts held on 3.3.2025 at 11:00 AM.

66th meeting of the Multidisciplinary Committee of Experts was held on 3.3.2025 at 11:00 AM under the convenorship of Shri Sanjay Kumar, Advisor (Cost). The following members attended the meeting: -

1. Shri Ranga Chandrashekar, Joint Drugs Controller, CDSCO through Video Conferencing
2. Dr. J. J. Cherian, Scientist-E (Med), ICMR
3. Dr. Rakesh Kr. Singh, Associate Professor, NIPER Raebareli, through Video Conferencing
4. Prof. Y. K. Gupta, Principal Scientific Advisor (Projects), THSTI-DBT, GoI & Ex-HoD, Pharmacology & Dean (Academics), AIIMS, New Delhi – Co-opted member, through Video Conferencing
5. Dr. Shashi Bhushan, Representative of Indian Pharmacopoeia Commission, through Video Conferencing

The following officers of NPPA attended and presented the cases before the Committee:

1. Ms. Rashmi Tahiliani, Director (Pricing)
2. Shri Mahaveer Saini, Deputy Director (Pricing)
3. Ms. Yuvika Panwar, Assistant Director (Pricing)

Agenda Item No. 1(a): Retail price fixation of composition: - Each film coated bilayered tablet contains: Empagliflozin 25mg + Metformin Hydrochloride IP 1000mg (as extended release) for M/s Pure and Cure healthcare Pvt. Ltd. (Manufacturer) & M/s Alkem Laboratories Ltd. (Marketer) (F.No. 4414).

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Pure and Cure Healthcare Pvt. Ltd.
2	Marketer Name	M/s Alkem Laboratories Ltd. (Applicant)
3	Date of Application	9.1.2025
4	Patented Component	Empagliflozin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD, M/s Cipla and M/s Torrent
7	Date of Patent Expiry	10.03.2025
8	<u>Calculation of Retail price</u>	
A	Price as on 6 months prior to application date i.e. MAT & PTR for June 2024 of Empagliflozin 25mg	47.73
B	50% of Empagliflozin 25mg	23.87
C	Ceiling Price for Metformin 1000mg Modified release as on June 2024 (S.O. 1547(E) dated 26.3.2024) (i.e. price	4.05

	applicable for month ending 6 months prior to month of receipt of application)	
D	Total	27.92
E	Less: 20% of the lower of (B) and (C) based on inference drawn from the Pronab Sen Committee Report	0.81
F	Worked out Retail Price (D-E) excluding taxes	27.11
G	Claimed Retail price	27.68
H	Recommended Price (Lower of worked out and claimed price) per tablet	27.11

Agenda Item No. 1(b) Retail price fixation of each film coated tablets contains: Empagliflozin 25mg + Metformin Hydrochloride IP 1000mg for M/s Pure and Cure Healthcare Pvt. Ltd. (Manufacturer) & M/s Aristo Pharmaceuticals Pvt. Limited (Marketer) (F. No. 4453)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Pure and Cure Healthcare Pvt. Ltd.
2	Marketer Name	M/s Aristo Pharmaceuticals Pvt. Ltd. (Applicant)
3	Date of Application	24.1.2025
4	Patented Component	Empagliflozin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD, M/s Cipla and M/s Torrent
7	Date of Patent Expiry	10.03.2025
8	Calculation of Retail price	
A	Price as on 6 months prior to application date i.e. MAT & PTR for June 2024 of Empagliflozin 25mg	47.73
B	50% of Empagliflozin 25mg	23.87
C	Ceiling Price for Metformin 1000mg Modified release as on June 2024 (S.O. 1547(E) dated 26.3.2024) (i.e. price applicable for month ending 6 months prior to month of receipt of application)	4.05
D	Total	27.92
E	Less: 20% of the lower of (B) and (C) based on inference drawn from the Pronab Sen Committee Report	0.81
F	Worked out Retail Price (D-E)	27.11
G	Claimed Retail price	29.92

H	Recommended Price (Lower of worked out and claimed price) per tablet	27.11
----------	---	--------------

Agenda Item No. 1(c): Retail price fixation of each film coated tablets contains: Empagliflozin 25mg + Metformin Hydrochloride IP (as sustained release) 1000mg for M/s Abbott Healthcare Pvt. Limited (Manufacturer) & M/s Abbott Healthcare Pvt. Limited (Marketer) (File No. 4418)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Abbott Healthcare Pvt. Limited
2	Marketer Name	M/s Abbott Healthcare Pvt. Limited (Applicant)
3	Date of Application	10.1.2025
4	Patented Component	Empagliflozin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD, M/s Cipla and M/s Torrent
7	Date of Patent Expiry	10.03.2025
8	Calculation of Retail price	
A	Price as on 6 months prior to application date i.e. MAT & PTR for June 2024 of Empagliflozin 25mg	47.73
B	50% of Empagliflozin 25mg	23.87
C	Ceiling Price for Metformin 1000mg Modified release as on June 2024 (S.O. 1547(E) dated 26.3.2024) (i.e. price applicable for month ending 6 months prior to month of receipt of application)	4.05
D	Total	27.92
E	Less: 20% of the lower of (B) and (C) based on inference drawn from the Pronab Sen Committee Report	0.81
F	Worked out Retail Price (D-E)	27.11
G	Claimed Retail price	21.43
H	Recommended Price (Lower of worked out and claimed price) per tablet	21.43

R

Agenda Item No. 1(d): Retail price fixation of each film coated bilayered tablets contains: Empagliflozin 25 mg + Metformin Hydrochloride IP(in extended release form) 1000 mg for M/s Pure and Cure Healthcare Pvt. Ltd (Manufacturer) & M/s Intas Pharmaceutical Ltd. (Marketer) (F. No. 4422)

1.The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Pure and Cure Healthcare Pvt. Ltd
2	Marketer Name	M/s Intas Pharmaceutical Ltd.
3	Date of Application	13.1.2025
4	Patented Component	Empagliflozin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD, M/s Cipla and M/s Torrent
7	Date of Patent Expiry	10.03.2025
8	Calculation of Retail price	
A	Price as on 6 months prior to application date i.e. MAT & PTR for June 2024 of Empagliflozin 25mg	47.73
B	50% of Empagliflozin 25mg	23.87
C	Ceiling Price for Metformin 1000mg Modified release as on June 2024 (S.O. 1547(E) dated 26.3.2024) (i.e. price applicable for month ending 6 months prior to month of receipt of application)	4.05
D	Total	27.92
E	Less: 20% of the lower of (B) and (C) based on inference drawn from the Pronab Sen Committee Report	0.81
F	Worked out Retail Price (D-E)	27.11
G	Claimed Retail price	15.00
H	Recommended Price (Lower of worked out and claimed price) per tablet	15.00

Agenda Item No. 1(e): Retail price fixation of each film coated tablets contains: Empagliflozin 25mg + Metformin Hydrochloride IP 1000mg (as extended release) for M/s Pure and Care Healthcare Pvt. Limited (Manufacturer) & M/s Cadila Pharmaceuticals Limited (Marketer) (F. No. 4470)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Pure and Care Healthcare Pvt. Limited
2	Marketer Name	M/s Cadila Pharmaceuticals Limited (Applicant)
3	Date of Application	28.1.2025
4	Patented Component	Empagliflozin

5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD, M/s Cipla and M/s Torrent
7	Date of Patent Expiry	10.03.2025
8	<u>Calculation of Retail price</u>	
A	Price as on 6 months prior to application date i.e. MAT & PTR for June 2024 of Empagliflozin 25mg	47.73
B	50% of Empagliflozin 25mg	23.87
C	Ceiling Price for Metformin 1000mg Modified release as on June 2024 (S.O. 1547(E) dated 26.3.2024) (i.e. price applicable for month ending 6 months prior to month of receipt of application)	4.05
D	Total	27.92
E	Less: 20% of the lower of (B) and (C) based on inference drawn from the Pronab Sen Committee Report	0.81
F	Worked out Retail Price (D-E)	27.11
G	Claimed Retail price	53.57
H	Recommended Price (Lower of worked out and claimed price) per tablet	27.11

Agenda Item No. 1(f): Retail price fixation of each Film Coated Bilayered Tablet contains: Empagliflozin 25 mg + Metformin Hydrochloride IP 1000 mg (As Extended Release) for M/s Zydus Healthcare Ltd. (Manufacturer & Marketer) (F.No. 4390)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Zydus Healthcare Ltd.
2	Marketer Name	M/s Zydus Healthcare Ltd. (Applicant)
3	Date of Application	31.12.2024
4	Patented Component	Empagliflozin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD, M/s Cipla and M/s Torrent
7	Date of Patent Expiry	10.03.2025
8	<u>Calculation of Retail price</u>	
A	Price as on 6 months prior to application date i.e. MAT & PTR for May 2024 of Empagliflozin 25mg	47.73
B	50% of Empagliflozin 25mg	23.87
C	Ceiling Price for Metformin 1000mg Modified release as on May 2024 (S.O. 1547(E) dated 26.3.2024) (i.e. price	4.05

	applicable for month ending 6 months prior to month of receipt of application)	
D	Total	27.92
E	Less: 20% of the lower of (B) and (C) based on inference drawn from the Pronab Sen Committee Report	0.81
F	Worked out Retail Price (D-E)	27.11
G	Claimed Retail price	60.00
H	Recommended Price (Lower of worked out and claimed price) per tablet	27.11

Agenda Item No.1(g): Retail price fixation of each film coated bilayered tablets contains: Empagliflozin 25 mg + Metformin Hydrochloride IP(in extended release form) 1000 mg for M/s Pure and Cure Healthcare Pvt. Ltd (Manufacturer) M/s ERIS Lifesciences Limited (Marketer) (F.No. 4429)

1.The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Pure and Cure Healthcare Pvt. Ltd
2	Marketer Name	M/s ERIS Lifesciences Limited
3	Date of Application	20.1.2025
4	Patented Component	Empagliflozin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD, M/s Cipla and M/s Torrent
7	Date of Patent Expiry	10.03.2025
8	Calculation of Retail price	
A	Price as on 6 months prior to application date i.e. MAT & PTR for June 2024 of Empagliflozin 25mg	47.73
B	50% of Empagliflozin 25mg	23.87
C	Ceiling Price for Metformin 1000mg Modified release as on June 2024 (S.O. 1547(E) dated 26.3.2024) (i.e. price applicable for month ending 6 months prior to month of receipt of application)	4.05
D	Total	27.92
E	Less: 20% of the lower of (B) and (C) based on inference drawn from the Pronab Sen Committee Report	0.81
F	Worked out Retail Price (D-E)	27.11
G	Claimed Retail price	42.41
H	Recommended Price (Lower of worked out and claimed price) per tablet	27.11

Agenda Item No. 1(h): Retail price fixation of each Film Coated Bilayered Tablet contains: Empagliflozin 25 mg + Metformin Hydrochloride IP 1000 mg (As Extended Release) for M/s Pure and Cure Healthcare Pvt. Ltd. (Manufacturer) & M/s Torrent Pharmaceuticals Ltd. (Marketer) (F. No. 4447)

1.The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Pure and Cure Healthcare Pvt. Ltd.
2	Marketer Name	M/s Torrent Pharmaceuticals Ltd. (Applicant)
3	Date of Application	22.1.2025
4	Patented Component	Empagliflozin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD, M/s Cipla and M/s Torrent
7	Date of Patent Expiry	10.03.2025
8	Calculation of Retail price	
A	Price as on 6 months prior to application date i.e. MAT & PTR for June 2024 of Empagliflozin 25mg	47.73
B	50% of Empagliflozin 25mg	23.87
C	Ceiling Price for Metformin 1000mg Modified release as on June 2024 (S.O. 1547(E) dated 26.3.2024) (i.e. price applicable for month ending 6 months prior to month of receipt of application)	4.05
D	Total	27.92
E	Less: 20% of the lower of (B) and (C) based on inference drawn from the Pronab Sen Committee Report	0.81
F	Worked out Retail Price (D-E)	27.11
G	Claimed Retail price	27.00
H	Recommended Price (Lower of worked out and claimed price) per tablet	27.00

Agenda Item No. 1(i): Retail price fixation of each Film Coated Bilayered Tablet contains: Empagliflozin 25 mg + Metformin Hydrochloride IP 1000 mg (As Extended Release) for M/s Pure and Cure Healthcare Pvt. Ltd. (Manufacturer) & M/s Cipla Ltd. (Marketer) (F. No. 4457)

1.The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Pure and Cure Healthcare Pvt. Ltd.
2	Marketer Name	M/s Cipla Ltd. (Applicant)

Handwritten signature

3	Date of Application	24.1.2025
4	Patented Component	Empagliflozin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD, M/s Cipla and M/s Torrent
7	Date of Patent Expiry	10.03.2025
8	Calculation of Retail price	
A	Price as on 6 months prior to application date i.e. MAT & PTR for June 2024 of Empagliflozin 25mg	47.73
B	50% of Empagliflozin 25mg	23.87
C	Ceiling Price for Metformin 1000mg Modified release as on June 2024 (S.O. 1547(E) dated 26.3.2024) (i.e. price applicable for month ending 6 months prior to month of receipt of application)	4.05
D	Total	27.92
E	Less: 20% of the lower of (B) and (C) based on inference drawn from the Pronab Sen Committee Report	0.81
F	Worked out Retail Price (D-E)	27.11
G	Claimed Retail price	35.00
H	Recommended Price (Lower of worked out and claimed price) per tablet	27.11

Agenda Item No. 2(a): Retail price fixation of each film coated tablets contains: Empagliflozin 10mg + Metformin Hydrochloride IP 1000mg (As Extended Release) for M/s Pure and Cure Healthcare Pvt. Limited (Manufacturer) & M/s Cipla Limited (Marketer) (F.No. 4455)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Pure and Cure Healthcare Pvt. Limited
2	Marketer Name	M/s Cipla Limited (Applicant)
3	Date of Application	24.1.2025
4	Patented Component	Empagliflozin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD, M/s Cipla and M/s Torrent
7	Date of Patent Expiry	10.03.2025
8	Calculation of Retail price	
A	Price as on 6 months prior to application date i.e. MAT & PTR for June 2024 of Empagliflozin 10mg	39.44
B	50% of Empagliflozin 10mg	19.72
C	Ceiling Price for Metformin 1000mg Modified release as on June 2024 (S.O.	4.05

	1547(E) dated 26.3.2024) (i.e. price applicable for month ending 6 months prior to month of receipt of application)	
D	Total	23.77
E	Less: 20% of the lower of (B) and (C) based on inference drawn from the Pronab Sen Committee Report	0.81
F	Worked out Retail Price (D-E)	22.96
G	Claimed Retail price	18.00
H	Recommended Price (Lower of worked out and claimed price) per tablet	18.00

Agenda Item No. 2(b): Retail price fixation of each film Coated bilayered tablet contains: Empagliflozin 10 mg + Metformin Hydrochloride IP 1000 mg (As Extended Release) for M/s Pure and Cure Healthcare Pvt. Ltd. (Manufacturer) & M/s Alkem Laboratories Limited (Marketer) (F.No. 4409)

1. The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Pure and Cure Healthcare Pvt. Ltd.
2	Marketer Name	M/s Alkem Laboratories Limited (Applicant)
3	Date of Application	9.1.2025
4	Patented Component	Empagliflozin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD, M/s Cipla and M/s Torrent
7	Date of Patent Expiry	10.3.2025
8	Calculation of Retail price	
A	Price as on 6 months prior to application date i.e. MAT & PTR for June 2024 of Empagliflozin 10mg	39.44
B	50% of Empagliflozin 10mg	19.72
C	Ceiling Price for Metformin 1000mg Modified release as on June 2024 (S.O. 1547(E) dated 26.3.2024) (i.e. price applicable for month ending 6 months prior to month of receipt of application)	4.05
D	Total	23.77
E	Less: 20% of the lower of (B) and (C) based on inference drawn from the Pronab Sen Committee Report	0.81
F	Worked out Retail Price (D-E)	22.96
G	Claimed Retail price	21.43

H	Recommended Price (Lower of worked out and claimed price) per tablet	21.43
----------	---	--------------

Agenda Item No. 2(c): Retail price fixation of Each film coated tablet contains: Empagliflozin 10mg + Metformin Hydrochloride IP 1000mg (as Sustained Release) for M/s Abbott Healthcare Pvt Limited (Manufacturer & Marketer) (F.No. 4419)

1.The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Abbott Healthcare Pvt Limited
2	Marketer Name	M/s Abbott Healthcare Pvt Limited (Applicant)
3	Date of Application	10.1.2025
4	Patented Component	Empagliflozin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD, M/s Cipla and M/s Torrent
7	Date of Patent Expiry	10.03.2025
8	Calculation of Retail price	
A	Price as on 6 months prior to application date i.e. MAT & PTR for June 2024 of Empagliflozin 10mg	39.44
B	50% of Empagliflozin 10mg	19.72
C	Ceiling Price for Metformin 1000mg Modified release as on June 2024 (S.O. 1547(E) dated 26.3.2024) (i.e. price applicable for month ending 6 months prior to month of receipt of application)	4.05
D	Total	23.77
E	Less: 20% of the lower of (B) and (C) based on inference drawn from the Pronab Sen Committee Report	0.81
F	Worked out Retail Price (D-E)	22.96
G	Claimed Retail price	16.96
H	Recommended Price (Lower of worked out and claimed price) per tablet	16.96

Agenda Item No. 2(d): Retail price fixation of each film coated bilayered tablet contains Empagliflozin 10mg & Metformin Hydrochloride IP 1000mg (as extended release) for M/s Pure and care Healthcare Pvt Limited (Manufacturer) & M/s Cadila Pharmaceuticals Limited (Marketer) (F.No. 4468)

1.The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Pure and care Healthcare Pvt Limited
2	Marketer Name	M/s Cadila Pharmaceuticals Limited (Applicant)
3	Date of Application	28.1.2025
4	Patented Component	Empagliflozin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD, M/s Cipla and M/s Torrent
7	Date of Patent Expiry	10.3.2025
8	Calculation of Retail price	
A	Price as on 6 months prior to application date i.e. MAT & PTR for June 2024 of Empagliflozin 10mg	39.44
B	50% of Empagliflozin 10mg	19.72
C	Ceiling Price for Metformin 1000mg Modified release as on June 2024 (S.O. 1547(E) dated 26.3.2024) (i.e. price applicable for month ending 6 months prior to month of receipt of application)	4.05
D	Total	23.77
E	Less: 20% of the lower of (B) and (C) based on inference drawn from the Pronab Sen Committee Report	0.81
F	Worked out Retail Price (D-E)	22.96
G	Claimed Retail price	46.88
H	Recommended Price (Lower of worked out and claimed price) per tablet	22.96

Agenda Item No. 2(e): Retail price fixation of each film coated bilayered tablet contains Empagliflozin 10mg & Metformin Hydrochloride IP 1000mg (as extended release) for M/s Pure and care Healthcare Pvt Limited (Manufacturer) & M/s ERIS Lifesciences Ltd. (Marketer) (F.No. 4485)

1.The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Pure and Cure Healthcare Pvt. Ltd.
2	Marketer Name	M/s ERIS Lifesciences Ltd. (Applicant)
3	Date of Application	3.2.2025

4	Patented Component	Empagliflozin
5	Patent Holder	M/s Boehringer Ingelheim
6	License Holder	M/s Lupin LTD, M/s Cipla and M/s Torrent
7	Date of Patent Expiry	10.03.2025
8	<u>Calculation of Retail price</u>	
A	Price as on 6 months prior to application date i.e. MAT & PTR for July 2024 of Empagliflozin 10mg	39.44
B	50% of Empagliflozin 10mg	19.72
C	Ceiling Price for Metformin 1000mg Modified release as on July 2024 (S.O. 1547(E) dated 26.3.2024) (i.e price applicable for month ending 6 months prior to month of receipt of application)	4.05
D	Total	23.77
E	Less: 20% of the lower of (B) and (C) based on inference drawn from the Pronab Sen Committee Report	0.81
F	Worked out Retail Price (D-E)	22.96
G	Claimed Retail price	35.71
H	Recommended Price (Lower of worked out and claimed price) per tablet	22.96

Agenda Item No 3 Application from M/s Biological E Limited for exemption under Para 32 (i, ii & iii) of the DPCO, 2013 for the formulation Pneumococcal Polysaccharide Conjugate Vaccine (PNEUBEVAX 14)

1. The committee recalled that the matter was earlier placed in 64th meeting of MDC held on 6.12.2024, wherein the agenda was deferred and the committee directed that the matter may be pursued with DPIIT for nomination of suitable officer.

2. The representative of office of DPIIT attended the meeting and informed that the subject application as forwarded by NPPA is at an advanced stage of examination. The Committee requested that the comments may be shared with NPPA by 15th March 2025 so that the matter may be deliberated in next meeting for early disposal.

Agenda Item No 4 Application by M/s Intas Pharmaceuticals Private limited for exemption from the provisions of Drug Price Control Order 2013 under Para 32 (ii & iii) for the formulation "Clozapine Extended Release 12.5 mg/ 25 mg/ 50 mg/ 100 mg/200 mg capsule

1. The committee recalled that the matter was earlier placed in 64th meeting of MDC held on 6.12.2024, wherein the agenda was deferred and the committee directed that the matter may be pursued with DPIIT for nomination of suitable officer.

2. The representative of office of DPIIT attended the meeting and informed that the subject application as forwarded by NPPA is at an advanced stage of examination. The Committee

requested that the comments may be shared with NPPA by 15th March 2025 so that the matter may be deliberated in next meeting for early disposal.

Agenda Item No. 5(a): Retail price fixation of composition: Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg + Gliclazide IP 30mg (as sustained release form) + Metformin Hydrochloride IP 500mg (as sustained release form) for M/s Eris Lifesciences Limited (Manufacturer & Marketer) (F.No. 4342).

1.The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:

1	Manufacturer Name	M/s Eris Lifesciences Limited
2	Marketer Name	M/s Eris Lifesciences Limited (Applicant)
3	Date of Application	3.12.2024
4	Patented Component	Dapagliflozin
5	Patent Holder	M/s Astrazeneca
6	License Holder	M/s Sun Pharma, M/s Abbott Healthcare
7	Date of Patent Expiry	2.10.2020

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Dapagliflozin (10mg) + Metformin SR (500mg)	Option-II Gliclazide SR(30 mg) + Metformin SR (500mg)
A.	Retail price of FDC excluding Patent & License Holder under Option I	May 24	10.87	7.28
B.	Other Component excluding Patent & License Holder under Option II	May 24	7.15 (Gliclazide 30mg SR)	12.60 (Dapagliflozin 10mg)
C.	Total		18.02	19.88
D.	Less: 20% of lower of A&B		1.43	1.46
E.	Calculated Price of applied FDC		16.59	18.42
F.	Claimed Price		35.71	35.71
G	Recommended Price (Lower of worked out and claimed price) per tablet			16.59

Agenda Item No. 5(b): Retail price fixation of composition: Each film coated bilayered tablet contains: Dapagliflozin Propanediol USP eq. to Dapagliflozin 10mg + Gliclazide IP 60mg (as sustained release form) + Metformin Hydrochloride IP 500mg (as sustained release form) for M/s Eris Lifesciences Limited (Manufacturer & Marketer) (F.No. 4341).

1.The Committee deliberated on the matter and recommended retail price on the lines of DPCO amendment vide S.O. No. 2165(E) dated 11.05.2023 as below:



1	Manufacturer Name	M/s Eris Lifesciences Limited
2	Marketer Name	M/s Eris Lifesciences Limited (Applicant)
3	Date of Application	2.12.2024
4	Patented Component	Dapagliflozin
5	Patent Holder	M/s Astrazeneca
6	License Holder	M/s Sun Pharma, M/s Abbott Healthcare
7	Date of Patent Expiry	2.10.2020

Calculation of Retail Price

S.N.	Particulars	Data Month	Option-I Dapagliflozin (10mg) + Metformin SR (500mg)	Option-II Gliclazide SR(60 mg) + Metformin SR (500mg)
A.	Retail price of FDC excluding Patent & License Holder under Option I	May 24	10.87	13.10
B.	Other Component excluding Patent & License Holder under Option II	May 24	11.33 (Gliclazide 60mg SR)	12.60 (Dapagliflozin 10mg)
C.	Total		22.20	25.70
D.	Less: 20% of lower of A&B taking inference from the Pronab Sen Committee Report		2.17	2.52
E.	Calculated Price of applied FDC		20.03	23.18
F.	Claimed Price		40.18	40.18
G	Recommended Price (Lower of worked out and claimed price) per tablet			20.03

Agenda Item No. 6: Retail price fixation under Para 5 of DPCO, 2013 of Each uncoated dispersible tablet Contains: Methylprednisolone IP 4 mg for M/s. J.K. Printpack (Pharma Division) (Manufacturer) & M/s Biological E. Ltd. (Marketer) (F. No. 3992)

1. The committee noted that M/s Biological E. Ltd. has applied for retail price fixation of each uncoated dispersible tablet Contains: Methylprednisolone IP 4 mg. SLA license submitted by the company is for 'Each uncoated dispersible tablet containing: Methylprednisolone IP 4mg', whereas DCGI permission is for 'Methylprednisolone' i.e. without mentioning the strength and dosage form.

2. The committee in its 64th meeting held on 6.12.2024 deliberated the communication dated 25.10.2024 received from O/o DCGI. Further, the matter was placed before the 66th meeting of the MDC to consider the inputs provided by the O/o DCGI vide email dated 6.1.2025 informing therein that "approval status of Methylprednisolone IP 4mg dispersible tablet is not available". The committee deliberated on the matter and decided that the application may be returned to the applicant. The applicant may apply afresh along with the approval/ NOC from the O/o DCGI.

Dr

Agenda Item No. 7: Application for grant of separate price/special price for Omeprazole Delayed release orally disintegrating tablet 20 mg "OMEZ ODT" under the provision of Para 11 (3) or Para 32(3) DPCO 2013.

1. The committee noted that the matter was earlier deliberated in the 64th meeting of MDC held on 06.12.2024, wherein the Committee deliberated upon the technical justification provided by the applicant. It was noted that 'Delayed Release' is common to all formulation of Omeprazole tablet & capsules and are always 'Enteric coated' and it acts only in intestine. Further, the shortcomings of omeprazole with sodium bicarbonate as mentioned by the applicant were not found to be tenable. Hence, there appears to be no incremental specified therapeutic rationale of Omeprazole Orally Disintegrating tablet over the Omeprazole Enteric Coated Tablets. Accordingly, the Committee rejected the application for special/separate price for Omeprazole Delayed release orally disintegrating tablet 20 mg.

2. However, based on the representation of the company dated 24.12.2024, the matter was again placed in 65th meeting of MDC held on 23.1.2025, wherein the applicant gave a detailed presentation of the case. The Committee noted that the applicant mentioned that approximately 8-19% of the general population in India is estimated to be suffering from GERD (Gastro Esophageal Reflux Disease). PPIs (Proton Pump Inhibitors) like Omeprazole have been used for its management for many decades with established clinical effectiveness & safety profile. However, 49% of GERD patients have alarming symptoms of which Dysphagia is the most common in almost two-third of GERD cases. The applicant also stated that the subject formulation does not have Sodium bicarbonate. Applicant stated that these facts have been taken from a survey conducted by clinicians to assess clinical profiling of patients with Acid Peptic Disorders in India.

3. The Committee noted that the subject formulation is useful for a subset of population having Dysphagia for which other liquid formulations are also available. Since this does not have sodium bicarbonate as mentioned by the applicant, this could be useful for only subset of cardiac patients. The applicant informed that the label claim of the subject formulation and other already available formulation i.e. OMEZ Insta (Powder for oral suspension with Sodium bicarbonate as buffer) will be same. Hence, the committee noted that the usefulness of the subject formulation is limited to a subset of population (i.e. patients with GERD having cardiac disorders along with Dysphagia).

4. The committee deliberated upon the matter and directed the applicant to submit the study/supporting documents showing the usefulness of the subject formulation and other additional document in support of their claim. The applicant vide email dated 21.1.2025 submitted their response on the deliberations of the 65th meeting of MDC. The Committee deliberated upon the documents submitted by the applicant and was of view that matter requires further deliberations. Hence, the matter may be placed before the next meeting of the MDC.

Agenda Item No. 8: Application under para 11 (3) of DPCO, 2013 for special retail price of Paracetamol and Phenylephrine Hydrochloride sachet (Each sachet containing Paracetamol I.P. 500 mg and Phenylephrine HCl I.P. 10 mg) by M/s GlaxoSmithKline Asia Private Limited.

1. The committee recalled that the matter was deliberated in 65th meeting held on 23.1.2025 wherein the company was directed to appear before the committee. Accordingly, the applicant company i.e., M/S GSK Asia Pvt. Ltd. appeared before the committee and gave a detailed presentation.

2. The committee noted that the company submitted the pack shots of similar products and claimed advantages like faster solubility, faster disintegration hence better safety and efficacy, better AUC level, absorption in intestine, useful in patients who have difficulty in swallowing and claimed lower price compared to other companies.

3. The committee deliberated upon the matter that Paracetamol I.P. 500 mg and Phenylephrine HCl I.P. 10 mg is an old drug approved in 2008. The Committee noted that submission made by the Co. requires further deliberations. Hence, the matter may be placed before the next meeting of the MDC.

Agenda Item No. 9: Application to fix a separate Ceiling Price under Paragraph 11(3) of DPCO-2013, of a Scheduled formulation of Amoxicillin 200 mg + Clavulanic acid 28.5 mg Suspension in a Dual Chamber Pack with Novel Technology, being introduced in India for the first time -Seeking additional Price for Dual Chamber Pack over and above Existing Ceiling Price.

1. The committee recalled that the matter was deliberated in 65th meeting wherein the Committee deliberated upon the request of the applicant and directed that the company may submit the additional papers, if any, in justification of their claim and appear before the committee in next meeting to present the case.

2. The committee observed that the company has submitted additional literature/evidences/reports vide letter dated 17.02.2025. The representatives of the Co. made a detailed presentation in support of their claim. The committee deliberated upon the same was of view that the matter requires further deliberations. Hence, the matter may be placed before the next meeting of the MDC.

The meeting ended with a vote of thanks to all.

Rashmi
6/3/25
(Rashmi Tahiliani)
Director (Pricing)

Copy to:
All members of the Committee.

Computation of Retail Price based on May, 2024 Data under Para 5 of DPCO, 2013

Dapagliflozin 10mg tablet	Number of Companies cosisting of Market Share of 1% & Above					18
	Sum of MAT value considered for price calculation (in Lakhs)					34,710.22
	Sum of PTR per unit considered for price calculation					260.69
	Number of Packs considered					24
	Average PTR					10.86
	Add : 16% Retailer Margin					1.74
	Retail Price (without local taxes)					12.60
% Reduction with compared to Highest Price						26.07%

Minimum Price (Rs.)			4.21
Maximum Price (Rs.)			14.69
Average of all considered (Rs.)			10.86
Retail Price (Rs.)			12.6

S.No.	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	TOTAL MAT	4,01,91,39,342	100%	M3		
								MAT(Rs.)	SKU wise MAT %	Brandwise MAT (ignoring O% MAT)	Qualify (Y/N) Y=Yes N=No	Price per Unit (Rs.)	Price per Unit (Rs.) Considered
1	4 DAPA 10 MG TABLET 10	4 DAPA	4 CARE LIFESCIENCE PVT LTD	10 MG	10	TABLET	85	1760435.00	0.04%	0.04%	N	8.50	
2	4 DAPA M 10 MG TABLET 10	4 DAPA M	4 CARE LIFESCIENCE PVT LTD	10 MG	10	TABLET	110	706320.00	0.02%	0.02%	N	11.00	
3	SULIDAPA 10 MG TABLET 15	SULIDAPA	AAREEN HEALTHCARE	10 MG	15	TABLET	159.64	5575418.24	0.14%	0.14%	N	10.64	
4	GLEDEPA 10 MG TABLET 14	GLEDEPA	ABBOTT HEALTHCARE PVT. LTD	10 MG	14	TABLET	573.5						
5	LVEFFECT 10 MG TABLET 15	LVEFFECT	ABBOTT HEALTHCARE PVT. LTD	10 MG	15	TABLET	176.79						
6	GLUJECT 10 MG TABLET 15	GLUJECT	ABBOTT HEALTHCARE PVT. LTD	10 MG	15	TABLET	176.79						
7	DAXIGA 10 MG TABLET 10	DAXIGA	ACMEDIX PHARMA LLP	10 MG	10	TABLET	31.43	8022947.52	0.20%	0.20%	N	3.14	
8	DARTDAPA 10 MG TABLET 10	DARTDAPA	ADDII BIOTECH PVT.LTD	10 MG	10	TABLET	203.11	2461498.41	0.06%	0.06%	N	20.31	
9	DAPALEX 10 MG TABLET 10	DAPALEX	AJANTA PHARMA LTD	10 MG	10	TABLET	117.86	1608906.86	0.04%	0.71%	N	11.79	
10	DAPANTA 10 MG TABLET 10	DAPANTA	AJANTA PHARMA LTD	10 MG	10	TABLET	38.4	541208.32	0.01%	0.01%	N	3.84	
11	DAPALEX 10 MG TABLET 15	DAPALEX	AJANTA PHARMA LTD	10 MG	15	TABLET	174.29	26764700.23	0.67%	0.71%	N	11.62	
12	DAPASIS 10 MG TABLET 10	DAPASIS	AKESSIS PHARMA (P) LTD	10 MG	10	TABLET	109.07	13699106.73	0.34%	0.34%	N	10.91	
13	SWITDAPA 10 MG TABLET 10	SWITDAPA	AKUMENTIS HEALTHCARE LTD	10 MG	10	TABLET	85	11157015.00	0.28%	0.28%	N	8.50	
14	LINADAPA 10 MG TABLET 10	LINADAPA	AKUMENTIS HEALTHCARE LTD	10 MG	10	TABLET	125	11159000.00	0.28%	0.28%	N	12.50	
15	VOAGE 10 MG TABLET 10	VOAGE	ALEMBIC LTD	10 MG	10	TABLET	92.86	82733488.02	2.06%	2.06%	Y	9.29	9.29
16	DAPANORM 10 MG TABLET 10	DAPANORM	ALKEM LABORATORIES LTD.	10 MG	10	TABLET	125	436790375.00	10.87%	10.87%	Y	12.50	12.50
17	FLOZIMAX 10 MG TABLET 15	FLOZIMAX	ALNICHE LIFE SCIENCES PVT.LTD	10 MG	15	TABLET	139.29	36211.34	0.00%	0.00%	N	9.29	
18	DAPAZOL 10 MG TABLET 10	DAPAZOL	ALTEUS BIOGENICS PVT.LTD.	10 MG	10	TABLET	116.68	13134378.73	0.33%	0.33%	N	11.67	
19	DAPCARD 10 MG TABLET 10	DAPCARD	ALVIO PHARMACEUTICALS PVT.LTD	10 MG	10	TABLET	92.86	9318222.42	0.23%	0.23%	N	9.29	
20	DAPAYES 10 MG TABLET 10	DAPAYES	ANAX LIFE SCIENCES PVT.LTD	10 MG	10	TABLET	78.57	281581.86	0.01%	0.01%	N	7.86	
21	DAPATREND 10 MG TABLET 14	DAPATREND	ANTHEM BIOPHARMA PVT LTD	10 MG	14	TABLET	117.86	2173543.22	0.05%	0.05%	N	8.42	
22	DAPRICA 10 MG TABLET 10	DAPRICA	APRICA HEALTHCARE PVT LTD	10 MG	10	TABLET	120.8	33829630.96	0.84%	0.84%	N	12.08	
23	GLUFLOZIN 10 MG TABLET 15	GLUFLOZIN	ARISTO PHARMACEUTICALS PVT.LTD	10 MG	15	TABLET	121.43	38145348.98	0.95%	0.95%	N	8.10	
24	FORXIGA 10 MG TABLET 14	FORXIGA	ASTRAZENECA PHARMA INDIA LTD	10 MG	14	TABLET	362.86						
25	DAPATEN 10 MG TABLET 15	DAPATEN	BAL PHARMA	10 MG	15	TABLET	128.93	707526.25	0.02%	0.02%	N	8.60	
26	BIOXIGA 10 MG TABLET 10	BIOXIGA	BIOS LAB PVT.LTD	10 MG	10	TABLET	102.85	721910.95	0.02%	0.02%	N	10.29	

27	DIABIZ (BLUE) 10 MG TABLET 15	DIABIZ (BLUE)	BLUE CROSS LABORATORIES LTD	10 MG	15	TABLET	75	15902850.00	0.40%	0.40%	N	5.00	
28	DAPADEL 10 MG TABLET 10	DAPADEL	CADELL HEALTH CARE PVT.LTD	10 MG	10	TABLET	92.14	2443314.40	0.06%	0.06%	N	9.21	
29	ZANELLA 10 MG TABLET 10	ZANELLA	CADOMED PHARMACEUTICALS INDIA PVT.LT	10 MG	10	TABLET	86.98	672044.54	0.02%	0.02%	N	8.70	
30	DAPASACH 10 MG TABLET 10	DAPASACH	CIPLA LTD.	10 MG	10	TABLET	71.43	16977696.69	0.42%	0.42%	N	7.14	
31	GLUSENT 10 MG TABLET 14	GLUSENT	CKRIS LABORATORIES PVT LTD	10 MG	14	TABLET	129.6	3335520.96	0.08%	0.08%	N	9.26	
32	GLIFDAPA 10 MG TABLET 10	GLIFDAPA	CMR LIFE SCIENCES	10 MG	10	TABLET	96.43	2060516.24	0.05%	0.05%	N	9.64	
33	DAPABITE 10 MG TABLET 10	DAPABITE	CORONA	10 MG	10	TABLET	128.75	83982595.00	2.09%	2.09%	Y	12.88	12.88
34	DIOSGLT 10 MG TABLET 15	DIOSGLT	DIOS LIFESCIENCES PRIVATE LIMITED	10 MG	15	TABLET	147.32	561756.28	0.01%	0.01%	N	9.82	
35	DAPLO 10 MG TABLET 10	DAPLO	DR. REDDYS LABORATORIES LTD	10 MG	10	TABLET	142.5	120093618.88	2.99%	2.99%	Y	14.25	14.25
36	ESGEDAP 10 MG TABLET 14	ESGEDAP	EAST WEST PHARMA	10 MG	14	TABLET	159.51	7702888.17	0.19%	0.19%	N	11.39	
37	DAPACOOOL 10 MG TABLET 10	DAPACOOOL	ECON HEALTHCARE PVT LTD	10 MG	10	TABLET	78.57	392535.72	0.01%	0.01%	N	7.86	
38	DAFAX 10 MG TABLET 15	DAFAX	ELBRIT LIFE SCIENCES PVT.LTD	10 MG	15	TABLET	150	6688950.00	0.17%	0.17%	N	10.00	
39	DAPADER 10 MG TABLET 14	DAPADER	ELDER PROJECTS LIMITED	10 MG	14	TABLET	55.14	4595880.04	0.11%	0.11%	N	3.94	
40	ELDAPA 10 MG TABLET 10	ELDAPA	EL-DORADO BIO-TECH PVT LTD	10 MG	10	TABLET	78.57	2511296.94	0.06%	0.06%	N	7.86	
41	XGLET 10 MG TABLET 10	XGLET	ELINOR PHARMA	10 MG	10	TABLET	140	3096520.00	0.08%	0.08%	N	14.00	
42	EMILDAP 10 MG TABLET 15	EMILDAP	EMCURE PHARMACEUTICALS LTD	10 MG	15	TABLET	175.46	11205301.14	0.28%	0.28%	N	11.70	
43	DAPAGZA 10 MG TABLET 15	DAPAGZA	EMCURE PHARMACEUTICALS LTD	10 MG	15	TABLET	175.46	4540272.44	0.11%	0.11%	N	11.70	
44	DAPAZEP 10 MG TABLET 10	DAPAZEP	ERGOS LIFE SCIENCES	10 MG	10	TABLET	85.71	491375.43	0.01%	0.01%	N	8.57	
45	DAPAJUST 10 MG TABLET 10	DAPAJUST	ERINYLE PHARMA	10 MG	10	TABLET	140	7394240.00	0.18%	0.18%	N	14.00	
46	GLUXIT 10 MG TABLET 10	GLUXIT	ERIS LIFESCIENCES LTD	10 MG	10	TABLET	108.75	190604791.42	4.74%	4.74%	Y	10.88	10.88
47	MYODA 10 MG TABLET 10	MYODA	ERIS LIFESCIENCES LTD	10 MG	10	TABLET	125.21	5731134.25	0.14%	0.14%	N	12.52	
48	DAPARITE 10 MG TABLET 10	DAPARITE	ESWAR THERAPEUTICS PVT.LTD	10 MG	10	TABLET	127.86	3092625.78	0.08%	0.08%	N	12.79	
49	DIFLUP 10 MG TABLET 10	DIFLUP	EXELTIS	10 MG	10	TABLET	121.24	573685.77	0.01%	0.01%	N	12.12	
50	DIABFLOZ 10 MG TABLET 10	DIABFLOZ	FINECURE PHARMACEUTICALS	10 MG	10	TABLET	82.14	76707.89	0.00%	0.00%	N	8.21	
51	FLOZIDAP 10 MG TABLET 10	FLOZIDAP	FRANCO INDIAN PHARMACEUTICALS PVT LT	10 MG	10	TABLET	103.57	9981351.61	0.25%	0.25%	N	10.36	
52	DEXIGLU 10 MG TABLET 10	DEXIGLU	FUSION HEALTHCARE PVT LTD	10 MG	10	TABLET	114.29	16220964.43	0.40%	0.40%	N	11.43	
53	DAPA GOLD 10 MG TABLET 15	DAPA GOLD	HBC LIFESCIENCES PVT LTD	10 MG	15	TABLET	175.5	21255824.98	0.53%	0.53%	N	11.70	
54	DAPASMARK 10 MG TABLET 10	DAPASMARK	HEALING PHARMA INDIA PVT.LTD	10 MG	10	TABLET	46.8	6392599.20	0.16%	0.16%	N	4.68	
55	DAPADOT 10 MG TABLET 10	DAPADOT	HETERO HEALTHCARE LTD	10 MG	10	TABLET	103.57	583409.81	0.01%	0.01%	N	10.36	
56	DAPARAY 10 MG TABLET 10	DAPARAY	ICON LIFESCIENCES	10 MG	10	TABLET	82.14	3577892.21	0.09%	0.09%	N	8.21	
57	DIMPRIDE 10 MG TABLET 10	DIMPRIDE	INDCHEMIE HEALTH SPECIALITIES PVT. LTD.	10 MG	10	TABLET	99.29	1133097.48	0.03%	0.03%	N	9.93	
58	DIGLIZ 10 MG TABLET 10	DIGLIZ	INDCHEMIE HEALTH SPECIALITIES PVT. LTD.	10 MG	10	TABLET	99.29	350394.41	0.01%	0.01%	N	9.93	
59	DEPAJA 10 MG TABLET 10	DEPAJA	INDOCO REMEDIES LTD	10 MG	10	TABLET	82.14	22259.94	0.00%	0.00%	N	8.21	
60	DAPARYL 10 MG TABLET 10	DAPARYL	INTAS PHARMACEUTICALS LTD	10 MG	10	TABLET	111.43	251285556.93	6.25%	6.25%	Y	11.14	11.14
61	DAPAVEL 10 MG TABLET 10	DAPAVEL	INTAS PHARMACEUTICALS LTD	10 MG	10	TABLET	111.43	408073241.55	10.15%	10.15%	Y	11.14	11.14
62	T2C 10 MG TABLET 15	T2C	IPCA LABORATORIES PVT LTD.	10 MG	15	TABLET	200.29	28430965.21	0.71%	0.71%	N	13.35	
63	DAPABLESS 10 MG TABLET 10	DAPABLESS	JAGSONPAL PHARMACEUTICALS LTD	10 MG	10	TABLET	50	7650.00	0.00%	0.00%	N	5.00	
64	JODAPA 10 MG TABLET 15	JODAPA	JARUN PHARMACEUTICALS	10 MG	15	TABLET	117.86	12017916.36	0.30%	0.30%	N	7.86	
65	DAPACOSE 10 MG TABLET 10	DAPACOSE	JB CHEMICALS	10 MG	10	TABLET	103.62	79276967.88	1.97%	1.97%	Y	10.36	10.36
66	DAPAEASE 10 MG TABLET 10	DAPAEASE	JUBILANT GENERICS LIMITED	10 MG	10	TABLET	113.93	5981099.65	0.15%	0.15%	N	11.39	
67	DAPAEASE V 10 MG TABLET SR 1	DAPAEASE V	JUBILANT GENERICS LIMITED	10 MG	15	TABLET SR	148.5	5983969.50	0.15%	0.15%	N	9.90	
68	DEGLIFLO 10 MG TABLET 10	DEGLIFLO	KANAD LABS	10 MG	10	TABLET	203.39	1623458.98	0.04%	0.04%	N	20.34	
69	DMBEST 10 MG TABLET 10	DMBEST	KEPLER HEALTH CARE	10 MG	10	TABLET	92.86	2278320.10	0.06%	0.06%	N	9.29	
70	DAGLIPACK 10 MG TABLET 10	DAGLIPACK	KOYE PHARMACEUTICALS PVT. LTD.	10 MG	10	TABLET	99.29	1355705.66	0.03%	0.03%	N	9.93	
71	DAPACONIC 10 MG TABLET 15	DAPACONIC	LA RENON HEALTHCARE PVT.LTD	10 MG	15	TABLET	198.57	7670957.67	0.19%	0.19%	N	13.24	
72	DAPAHENZ 10 MG TABLET 15	DAPAHENZ	LA RENON HEALTHCARE PVT.LTD	10 MG	15	TABLET	198.57	48999331.77	1.22%	1.22%	Y	13.24	13.24
73	DAPAFORD 10 MG TABLET 15	DAPAFORD	LEEFORD HEALTHCARE	10 MG	15	TABLET	42	1151571.00	0.03%	0.03%	N	2.80	
74	DIFOZIN 10 MG TABLET 14	DIFOZIN	LINCOLN PHARMACEUTICALS LTD	10 MG	14	TABLET	149.29	938586.23	0.02%	0.02%	N	10.66	
75	SUGAFLO 10 MG TABLET 15	SUGAFLO	LLOYD HEALTHCARE PVT.LTD	10 MG	15	TABLET	176.8	17704575.20	0.44%	0.44%	N	11.79	
76	DAPATURN 10 MG TABLET 10	DAPATURN	LUPIN LTD	10 MG	10	TABLET	113.86	62608517.85	1.56%	1.56%	Y	11.39	11.39
77	DAMITA 10 MG TABLET 10	DAMITA	MACLEODS PHARMACEUTICALS PVT.LTD	10 MG	10	TABLET	117.07	80368320.86	2.00%	2.00%	Y	11.71	11.71
78	DAPAMAC 10 MG TABLET 10	DAPAMAC	MACLEODS PHARMACEUTICALS PVT.LTD	10 MG	10	TABLET	117.07	185735652.45	4.62%	4.62%	Y	11.71	11.71

79	JUSTOZA 10 MG TABLET 10	JUSTOZA	MANKIND PHARMACEUTICALS LTD.	10 MG	10	TABLET	70.71	2946697.83	0.07%	1.39%	Y	7.07	7.07
80	SGLTD 10 MG TABLET 10	SGLTD	MANKIND PHARMACEUTICALS LTD.	10 MG	10	TABLET	77.79	80789672.70	2.01%	2.01%	Y	7.78	7.78
81	JUSTOZA 10 MG TABLET 15	JUSTOZA	MANKIND PHARMACEUTICALS LTD.	10 MG	15	TABLET	116.68	52884295.65	1.32%	1.39%	Y	7.78	7.78
82	DAPABLI 10 MG TABLET 10	DAPABLI	MED MANOR ORGANICS PVT LTD.	10 MG	10	TABLET	98.57	2418168.68	0.06%	0.06%	N	9.86	
83	DAPIFIN 10 MG TABLET 10	DAPIFIN	MEDIART LIFESCIENCES PVT.LTD	10 MG	10	TABLET	125.57	10344.74	0.00%	0.00%	N	12.56	
84	GLIFLODAP 10 MG TABLET 10	GLIFLODAP	MEDICURE LIFE SCIENCES PVT.LTD	10 MG	10	TABLET	68.57	2639876.43	0.07%	0.07%	N	6.86	
85	DAPANOVA 10 MG TABLET 15	DAPANOVA	MEDLEY PHARMACEUTICALS	10 MG	15	TABLET	168.57	47134562.99	1.17%	1.17%	Y	11.24	11.24
86	ZUCAPRIDE 10 MG TABLET 15	ZUCAPRIDE	MICRO LABS LTD	10 MG	15	TABLET	151.43	84747735.14	2.11%	2.11%	Y	10.10	10.10
87	DAJIO 10 MG TABLET 15	DAJIO	MICRO LABS LTD	10 MG	15	TABLET	150.71	56750820.70	1.41%	1.41%	Y	10.05	10.05
88	VIVADAPA 10 MG TABLET 10	VIVADAPA	MITOCH PHARMA PVT LTD	10 MG	10	TABLET	100	18299800.00	0.46%	0.46%	N	10.00	
89	DAPAONE 10 MG TABLET 10	DAPAONE	MSN LABORATORIES LTD	10 MG	10	TABLET	117.64	48674957.16	1.21%	1.21%	Y	11.76	11.76
90	DAPNAT 10 MG TABLET 30	DAPNAT	NATCO PHARMA LTD	10 MG	30	TABLET	70.71	66325.98	0.00%	0.00%	N	2.36	
91	DAPNAT 10 MG TABLET 10	DAPNAT	NATCO PHARMA LTD	10 MG	10	TABLET	70.71	9247228.59	0.23%	0.23%	N	7.07	
92	DAPANEU 10 MG TABLET 10	DAPANEU	NEUCURE LIFESCIENCES PVT.LTD	10 MG	10	TABLET	181.5	1044136.50	0.03%	0.24%	N	18.15	
93	DAPANEU 10 MG TABLET 15	DAPANEU	NEUCURE LIFESCIENCES PVT.LTD	10 MG	15	TABLET	181.5	8338506.00	0.21%	0.24%	N	12.10	
94	DAPACARE 10 MG TABLET 10	DAPACARE	OCTALIFE PHARMACEUTICALS PVT.LTD	10 MG	10	TABLET	64.29	601827.96	0.01%	0.01%	N	6.43	
95	OPSICA 10 MG TABLET 15	OPSICA	OPSISCARE LIFESCIECSE PVT LTD	10 MG	15	TABLET	150	3621000.00	0.09%	0.09%	N	10.00	
96	DAPATAB 10 MG TABLET 10	DAPATAB	ORRIS PHARMACEUTICALS	10 MG	10	TABLET	107.14	3111774.16	0.08%	0.08%	N	10.71	
97	OZODAP 10 MG TABLET 15	OZODAP	OZONE PHARMACEUTICALS	10 MG	15	TABLET	53.57	3055739.94	0.08%	0.08%	N	3.57	
98	DAPABEST 10 MG TABLET 10	DAPABEST	PANACEA BIOTEC LTD	10 MG	10	TABLET	88.56	7284.80	0.00%	0.00%	N	8.86	
99	DAPAKEY 10 MG TABLET 10	DAPAKEY	PRECIA PHARMA	10 MG	10	TABLET	103.57	1222954.56	0.03%	0.03%	N	10.36	
100	GLIFOPRIME 10 MG TABLET 10	GLIFOPRIME	PRIMUS REMEDIES PVT LTD	10 MG	10	TABLET	62.5	2480327.50	0.06%	0.06%	N	6.25	
101	DPO 10 MG TABLET 10	DPO	RPG LIFE SCIENCES LTD.	10 MG	10	TABLET	94.29	4161360.87	0.10%	0.10%	N	9.43	
102	DAPASAN 10 MG TABLET 14	DAPASAN	SANATRA HEALTH CARE PVT.LTD	10 MG	14	TABLET	150	1970550.00	0.05%	0.05%	N	10.71	
103	SHIDAPA 10 MG TABLET 10	SHIDAPA	SHINE PHARMACEUTICALS LTD	10 MG	10	TABLET	94.29	404015.34	0.01%	0.01%	N	9.43	
104	DAPASIG 10 MG TABLET 10	DAPASIG	SIGNOVA PHARMA (P) LTD	10 MG	10	TABLET	84.29	631247.81	0.02%	0.02%	N	8.43	
105	DAPAGREAT 10 MG TABLET 15	DAPAGREAT	SINSAN PHARMACEUTICALS	10 MG	15	TABLET	150	750.00	0.00%	0.00%	N	10.00	
106	MDAPA 10 10 MG TABLET 15	MDAPA 10	SINSAN PHARMACEUTICALS	10 MG	15	TABLET	96.43	96.43	0.00%	0.00%	N	6.43	
107	DAPASPEC 10 MG TABLET 10	DAPASPEC	SPECTRA THERAPEUTICS PVT. LTD.	10 MG	10	TABLET	96.43	9426225.36	0.23%	0.23%	N	9.64	
108	OXRA 10 MG TABLET 14	OXRA	SUN PHARMA LABORATORIES LTD.	10 MG	14	TABLET	155						
109	DAPEFY 10 MG TABLET 14	DAPEFY	SUN PHARMA LABORATORIES LTD.	10 MG	14	TABLET	141.43						
110	DAPAGAIN 10 MG TABLET 15	DAPAGAIN	SYSTOPIC LABORATORIES LTD-MEM	10 MG	15	TABLET	63.22	69398490.60	1.73%	1.73%	Y	4.21	4.21
111	NOVAGLIF 10 MG TABLET 14	NOVAGLIF	TAB Q THERAPEUTICS	10 MG	14	TABLET	115	2731188.20	0.07%	0.07%	N	8.21	
112	DAPOXEE 10 MG TABLET 10	DAPOXEE	TALENT INDIA	10 MG	10	TABLET	77.86	454464.57	0.01%	0.01%	N	7.79	
113	DAPIXA 10 MG TABLET 10	DAPIXA	TAS MED (INDIA) PRIVATE LTD.	10 MG	10	TABLET	110	911130.00	0.02%	0.02%	N	11.00	
114	GLUCRETA 10 MG TABLET 10	GLUCRETA	TORRENT PHARMACEUTICALS LTD.	10 MG	10	TABLET	107.36	187973871.59	4.68%	4.68%	Y	10.74	10.74
115	DGSON 10 MG TABLET 10	DGSON	UNISON PHARMACEUTICALS	10 MG	10	TABLET	32.14	19023794.56	0.47%	0.47%	N	3.21	
116	UDAPA 10 MG TABLET 10	UDAPA	USV PVT LTD	10 MG	10	TABLET	100.86	566781769.14	14.10%	14.10%	Y	10.09	10.09
117	DAPGLIN 10 MG TABLET 10	DAPGLIN	VASU ORGANICS PVT.LTD	10 MG	10	TABLET	83.57	83.57	0.00%	0.00%	N	8.36	
118	DAPAVAS 10 MG TABLET 10	DAPAVAS	VASU ORGANICS PVT.LTD	10 MG	10	TABLET	91.93	728545.25	0.02%	0.02%	N	9.19	
119	FLOZIPA 10 MG TABLET 10	FLOZIPA	WALLACE PHARMACEUTICALS LTD.	10 MG	10	TABLET	100	7020300.00	0.17%	0.17%	N	10.00	
120	ZINODAP 10 MG TABLET 10	ZINODAP	WOCKHARDT LTD	10 MG	10	TABLET	187.39	12939361.35	0.32%	0.32%	N	18.74	
121	DAPASET 10 MG TABLET 14	DAPASET	WONSET HEALTH CARE PRIVATE LIMITED	10 MG	14	TABLET	103.57	2161054.89	0.05%	0.05%	N	7.40	
122	DAPAXIGA 10 MG TABLET 14	DAPAXIGA	ZERICO LIFESCIENCES PVT.LTD	10 MG	14	TABLET	139.29	71545.10	0.00%	0.00%	N	9.95	
123	DUPHABLESS 10 MG TABLET 10	DUPHABLESS	ZERICO LIFESCIENCES PVT.LTD	10 MG	10	TABLET	471.43	269657.96	0.01%	0.01%	N	47.14	
124	DAPAFOR 10 MG TABLET 10	DAPAFOR	ZUVENTUS HEALTHCARE LTD	10 MG	10	TABLET	82.43	2531608.43	0.06%	0.06%	N	8.24	
125	DAPAGLYN 10 MG TABLET 15	DAPAGLYN	ZYDUS CADILA - ZHL	10 MG	15	TABLET	220.39	141290045.49	3.52%	6.04%	Y	14.69	14.69
126	DAPAGLYN 10 MG TABLET 10	DAPAGLYN	ZYDUS CADILA - ZHL	10 MG	10	TABLET	146.93	101097096.59	2.52%	6.04%	Y	14.69	14.69
		Rs. Per tablet											
	Worked out Retail Price	12.60	Excluding GST										

Note: In view of DPCO Amendment Vide S.O. No. 2165(E) dated 11.05.2023, Patent Holder of Dapagliflozin i.e. M/s Astra Zeneca & License holder i.e. M/s Sun Pharma and M/s Abbott Healthcare is not considered for price fixation.

Computation of Retail Price based on May, 2024 Data under Para 5 of DPCO, 2013

Dapagliflozin 10mg + Metformin 500mg SR tablet	Number of Companies cosisting of Market Share of 1% & Above								15
	Sum of MAT value considered for price calculation (in Lakhs)								11,125.87
	Sum of PTR per unit considered for price calculation								206.06
	Number of Packs considered								22
	Average PTR								9.37
	Add : 16% Retailer Margin								1.50
	Retail Price (without local taxes)								10.87
	% Reduction with compared to Highest Price								36.17%

Minimum Price (Rs.)			5.64
Maximum Price (Rs.)			14.68
Average of all considered (Rs.)			9.37
Retail Price (Rs.)			10.87

S.No.	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	TOTAL MAT PTR (Rs.)	1,61,04,79,192 MAT(Rs.)	82% SKU wise MAT %	Brandwise MAT (ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	M3	
												Price per Unit (Rs.)	Price per Unit (Rs.) Considered
1	GLUJECT M 10/500 MG TABLET	GLUJECT M	ABBOTT HEALTHCARE PVT. LTD	10/500 MG	15	TABLET	122.36	8919793.76					
2	GLUJECT TRIO 10/500 MG TABLET	GLUJECT TRIO	ABBOTT HEALTHCARE PVT. LTD	10/500 MG	10	TABLET	157.11	12147116.76					
3	DAXIGA M 10/500 MG TABLET	DAXIGA M	ACMEDIX PHARMA LLP	10/500 MG	10	TABLET	41.43	2709314.85	0.17%	0.17%	N	4.14	
4	DAPALEX M 10/500 MG TABLET	DAPALEX M	AJANTA PHARMA LTD	10/500 MG	10	TABLET	117.86	2927760.26	0.18%	0.75%	N	11.79	
5	DAPANTA M 10/500 MG TABLET	DAPANTA M	AJANTA PHARMA LTD	10/500 MG	10	TABLET	45.6	61797.45	0.00%	0.00%	N	4.56	
6	DAPALEX M 10/500 MG TABLET	DAPALEX M	AJANTA PHARMA LTD	10/500 MG	15	TABLET	176.43	9233640.48	0.57%	0.75%	N	11.76	
7	DAPASIS M 10/500 MG TABLET	DAPASIS M	AKESSIS PHARMA (P) LTD	10/500 MG	10	TABLET ER	76.43	3723090.96	0.23%	0.23%	N	7.64	
8	SWITDAPA M 10/500 MG TABLET	SWITDAPA M	AKUMENTIS HEALTHCARE LTD	10/500 MG	10	TABLET XR	85	3707445.00	0.23%	0.23%	N	8.50	
9	VOAGE M 10/500 MG TABLET	VOAGE M	ALEMBIC LTD	10/500 MG	10	TABLET	93.36	40851355.07	2.54%	2.54%	Y	9.34	9.34
10	DONANCE M 10/500 MG TABLET	DONANCE M	ALEMBIC LTD	10/500 MG	10	TABLET	93.36	6329808.00	0.39%	0.39%	N	9.34	
11	DAPANORM M 10/500 MG TABLET	DAPANORM M	ALKEM LABORATORIES LTD.	10/500 MG	10	TABLET	97.86	111615396.27	6.93%	6.93%	Y	9.79	9.79
12	DAPAZOL M 10/500 MG TABLET	DAPAZOL M	ALTEUS BIOGENICS PVT.LTD.	10/500 MG	10	TABLET	129.64	9018852.42	0.56%	0.56%	N	12.96	
13	DAPAYES M 10/500 MG TABLET	DAPAYES M	ANAX LIFE SCIENCES PVT.LTD	10/500 MG	10	TABLET	78.57	132233.31	0.01%	0.01%	N	7.86	
14	DAPATREND M 10/500 MG TABLET	DAPATREND M	ANTHEM BIOPHARMA PVT LTD	10/500 MG	10	TABLET	76.64	2440912.92	0.15%	0.15%	N	7.66	
15	CIDIDAP M 10/500 MG TABLET	CIDIDAP M	APEX LABORATORIES LTD.	10/500 MG	10	TABLET	80	2069351.78	0.13%	0.13%	N	8.00	
16	DAPRICA M 10/500 MG TABLET	DAPRICA M	APRICA HEALTHCARE PVT LTD	10/500 MG	10	TABLET	98.3	7860068.54	0.49%	0.49%	N	9.83	
17	GLITUS M 10/500 MG TABLET	GLITUS M	ARETAEUS PHARMACEUTICALS	10/500 MG	10	TABLET	79.64	56864.04	0.00%	0.00%	N	7.96	
18	GLUFLOZIN MF 10/500 MG TABLET	GLUFLOZIN MF	ARISTO PHARMACEUTICALS PVT.LTD	10/500 MG	15	TABLET	121.43	7900022.61	0.49%	0.49%	N	8.10	
19	XIGDUO 10/500 MG TABLET XR	XIGDUO	ASTRAZENECA PHARMA INDIA LTD	10/500 MG	7	TABLET XR	348.57	83233682.35					
20	DAPATEN M 10/500 MG TABLET	DAPATEN M	BAL PHARMA	10/500 MG	15	TABLET	131.43	622421.36	0.04%	0.04%	N	8.76	
21	DIABIZ M 10/500 MG TABLET	DIABIZ M	BLUE CROSS LABORATORIES LTD	10/500 MG	15	TABLET	96.43	7182299.26	0.45%	0.45%	N	6.43	
22	DAPADEL M 10/500 MG TABLET	DAPADEL M	CADELL HEALTH CARE PVT.LTD	10/500 MG	10	TABLET	106.43	1431391.07	0.09%	0.09%	N	10.64	
23	ZANELLA M 10/500 MG TABLET	ZANELLA M	CADOMED PHARMACEUTICALS INDIA PVT.L	10/500 MG	10	TABLET	86.91	2607.30	0.00%	0.00%	N	8.69	
24	DAPASACH M 10/500 MG TABLET	DAPASACH M	CIPLA LTD.	10/500 MG	10	TABLET	81.04	6528737.84	0.41%	0.41%	N	8.10	
25	GLIFDAPA M 10/500 MG TABLET	GLIFDAPA M	CMR LIFE SCIENCES	10/500 MG	10	TABLET	81.43	328977.20	0.02%	0.02%	N	8.14	
26	DAPABITE M 10/500 MG TABLET	DAPABITE M	CORONA	10/500 MG	10	TABLET	102.57	38382475.43	2.38%	2.38%	Y	10.26	10.26
27	DAPLO M 10/500 MG TABLET	DAPLO M	DR. REDDYS LABORATORIES LTD	10/500 MG	10	TABLET	146.78	39670716.92	2.46%	2.46%	Y	14.68	14.68
28	DAFAX M 10/500 MG TABLET	DAFAX M	ELBRIT LIFE SCIENCES PVT.LTD	10/500 MG	15	TABLET	152.86	3023417.94	0.19%	0.19%	N	10.19	

29	EMILDAP M 10/500 MG TABLET	EMILDAP M	EMCURE PHARMACEUTICALS LTD	10/500 MG	10	TABLET	73.43	5228436.29	0.32%	0.32%	N	7.34	
30	DAPAGZA M 10/500 MG TABLET	DAPAGZA M	EMCURE PHARMACEUTICALS LTD	10/500 MG	10	TABLET	80.71	2717146.39	0.17%	0.17%	N	8.07	
31	DAPAZEP M 10/500 MG TABLET	DAPAZEP M	ERGOS LIFE SCIENCES	10/500 MG	10	TABLET	71.43	1061949.81	0.07%	0.07%	N	7.14	
32	GLUXIT M 10/500 MG TABLET 1	GLUXIT M	ERIS LIFESCIENCES LTD	10/500 MG	10	TABLET	98.92	51499928.24	3.20%	3.20%	Y	9.89	9.89
33	DEXIGLU M 10/500 MG TABLET	DEXIGLU M	FUSION HEALTHCARE PVT LTD	10/500 MG	10	TABLET	83.57	11409388.30	0.71%	0.71%	N	8.36	
34	DAPA GOLD M 10/500 MG TABLET	DAPA GOLD M	HBC LIFESCIENCES PVT LTD	10/500 MG	15	TABLET	102.14	13175979.38	0.82%	0.82%	N	6.81	
35	DAPARAY M 10/500 MG TABLET	DAPARAY M	ICON LIFESCIENCES	10/500 MG	10	TABLET	92.14	1511645.52	0.09%	0.09%	N	9.21	
36	DIMPRIDE M 10/500 MG TABLET	DIMPRIDE M	INDCHEMIE HEALTH SPECIALITIES PVT. LTD.	10/500 MG	10	TABLET	81.76	1278726.40	0.08%	0.08%	N	8.18	
37	DIGLIZ M 10/500 MG TABLET 10	DIGLIZ M	INDCHEMIE HEALTH SPECIALITIES PVT. LTD.	10/500 MG	10	TABLET	89.29	351624.02	0.02%	0.02%	N	8.93	
38	DAPAVEL M 10/500 MG TABLET	DAPAVEL M	INTAS PHARMACEUTICALS LTD	10/500 MG	10	TABLET	97.86	75574842.07	4.69%	4.69%	Y	9.79	9.79
39	DAPARYL M 10/500 MG TABLET	DAPARYL M	INTAS PHARMACEUTICALS LTD	10/500 MG	10	TABLET	97.86	59566050.16	3.70%	3.70%	Y	9.79	9.79
40	T2C M 10/500 MG TABLET 15	T2C M	IPCA LABORATORIES PVT LTD.	10/500 MG	15	TABLET	127.32	6553322.41	0.41%	0.41%	N	8.49	
41	JODAPA M 10/500 MG TABLET	JODAPA M	JARUN PHARMACEUTICALS	10/500 MG	15	TABLET	135.71	3114728.75	0.19%	0.19%	N	9.05	
42	DAPACOSE M 10/500 MG TABLET	DAPACOSE M	JB CHEMICALS	10/500 MG	10	TABLET	94.58	21954105.00	1.36%	1.36%	Y	9.46	9.46
43	DAPAEASE M 10/500 MG TABLET	DAPAEASE M	JUBILANT GENERICS LIMITED	10/500 MG	10	TABLET	72.78	1301796.62	0.08%	0.08%	N	7.28	
44	DEGLIFLO M 10/500 MG TABLET	DEGLIFLO M	KANAD LABS	10/500 MG	10	TABLET	90	339792.36	0.02%	0.02%	N	9.00	
45	DMBEST M 10/500 MG TABLET	DMBEST M	KEPLER HEALTH CARE	10/500 MG	10	TABLET	73.57	941616.17	0.06%	0.06%	N	7.36	
46	DAGLIPACK M 10/500 MG TABLET	DAGLIPACK M	KOYE PHARMACEUTICALS PVT. LTD.	10/500 MG	10	TABLET	99.29	363798.56	0.02%	0.02%	N	9.93	
47	DAPAHENZ M 10/500 MG TABLET	DAPAHENZ M	LA RENON HEALTHCARE PVT.LTD	10/500 MG	10	TABLET	120.71	14824274.39	0.92%	0.92%	N	12.07	
48	DAPAFORD M 10/500 MG TABLET	DAPAFORD M	LEEFORD HEALTHCARE	10/500 MG	15	TABLET	75	326013.00	0.02%	0.02%	N	5.00	
49	DIFOZIN M 10/500 MG TABLET	DIFOZIN M	LINCOLN PHARMACEUTICALS LTD	10/500 MG	10	TABLET	84.29	1420623.66	0.09%	0.09%	N	8.43	
50	SUGAFLO M 10/500 MG TABLET	SUGAFLO M	LLOYD HEALTHCARE PVT.LTD	10/500 MG	15	TABLET	139.79	15587144.16	0.97%	0.97%	N	9.32	
51	DAPATURN M 10/500 MG TABLET	DAPATURN M	LUPIN LTD	10/500 MG	10	TABLET	93.32	22076451.80	1.37%	1.37%	Y	9.33	9.33
52	DAPAMAC M 10/500 MG TABLET	DAPAMAC M	MACLEODS PHARMACEUTICALS PVT.LTD	10/500 MG	15	TABLET	111.23	45667367.41	2.84%	3.02%	Y	7.42	7.42
53	DAMITA M 10/500 MG TABLET	DAMITA M	MACLEODS PHARMACEUTICALS PVT.LTD	10/500 MG	10	TABLET	81.71	16367575.23	1.02%	1.26%	Y	8.17	8.17
54	DAPAMAC M 10/500 MG TABLET	DAPAMAC M	MACLEODS PHARMACEUTICALS PVT.LTD	10/500 MG	10	TABLET	81.71	2879542.11	0.18%	3.02%	Y	8.17	8.17
55	DAMITA M 10/500 MG TABLET	DAMITA M	MACLEODS PHARMACEUTICALS PVT.LTD	10/500 MG	15	TABLET	111.23	3843886.34	0.24%	1.26%	Y	7.42	7.42
56	JUSTOZA M 10/500 MG TABLET	JUSTOZA M	MANKIND PHARMACEUTICALS LTD.	10/500 MG	10	TABLET	78.24	4022396.64	0.25%	4.02%	Y	7.82	7.82
57	SGLTD M 10/500 MG TABLET 10	SGLTD M	MANKIND PHARMACEUTICALS LTD.	10/500 MG	10	TABLET	85.64	41384932.24	2.57%	2.57%	Y	8.56	8.56
58	JUSTOZA M 10/500 MG TABLET	JUSTOZA M	MANKIND PHARMACEUTICALS LTD.	10/500 MG	15	TABLET	129.08	60683376.80	3.77%	4.02%	Y	8.61	8.61
59	DAPABLIS M 10/500 MG TABLET	DAPABLIS M	MED MANOR ORGANICS PVT LTD.	10/500 MG	10	TABLET	84.29	146243.15	0.01%	0.01%	N	8.43	
60	DAPANOVA M 10/500 MG TABLET	DAPANOVA M	MEDLEY PHARMACEUTICALS	10/500 MG	15	TABLET	181.07	9957763.58	0.62%	0.62%	N	12.07	
61	ZUCAPRIDE M 10/500 MG TABLET	ZUCAPRIDE M	MICRO LABS LTD	10/500 MG	10	TABLET	109.29	78352186.80	4.87%	4.87%	Y	10.93	10.93
62	DAJIO M 10/500 MG TABLET 10	DAJIO M	MICRO LABS LTD	10/500 MG	10	TABLET	100	29598300.00	1.84%	1.84%	Y	10.00	10.00
63	DAPAONE M 10/500 MG TABLET	DAPAONE M	MSN LABORATORIES LTD	10/500 MG	10	TABLET	91	10361537.12	0.64%	0.64%	N	9.10	
64	DAPABEST M 10/500 MG TABLET	DAPABEST M	PANACEA BIOTEC LTD	10/500 MG	10	TABLET	76.64	13871.84	0.00%	0.00%	N	7.66	
65	GLIFOPRIME M 10/500 MG TABLET	GLIFOPRIME M	PRIMUS REMEDIES PVT LTD	10/500 MG	15	TABLET	139.14	1889832.28	0.12%	0.12%	N	9.28	
66	DPO M 10/500 MG TABLET 10	DPO M	RPG LIFE SCIENCES LTD.	10/500 MG	10	TABLET	102.14	1056945.72	0.07%	0.07%	N	10.21	
67	DAPASER MEX 10/500 MG TABLET	DAPASER MEX	SERDIA PHARMACEUTICALS (INDIA) PVT. LTD	10/500 MG	15	TABLET	160.71	2907404.61	0.18%	0.18%	N	10.71	
68	DAPASPEC M 10/500 MG TABLET	DAPASPEC M	SPECTRA THERAPEUTICS PVT. LTD.	10/500 MG	10	TABLET	72.79	5457545.08	0.34%	0.34%	N	7.28	
69	OXRAMET XR 10/500 MG TABLET	OXRAMET XR	SUN PHARMA LABORATORIES LTD.	10/500 MG	7	TABLET XR	82.14	169547024.64					
70	DAPEFY M 10/500 MG TABLET	DAPEFY M	SUN PHARMA LABORATORIES LTD.	10/500 MG	7	TABLET XR	82.14	14859676.32					
71	DAPAGAIN M 10/500 MG TABLET	DAPAGAIN M	SYSTOPIC LABORATORIES LTD-MEM	10/500 MG	15	TABLET	84.64	20280928.96	1.26%	1.26%	Y	5.64	5.64
72	DAPOXEE M 10/500 MG TABLET	DAPOXEE M	TALENT INDIA	10/500 MG	10	TABLET	89.29	2070367.23	0.13%	0.13%	N	8.93	
73	GLUCRETA M 10/500 MG TABLET	GLUCRETA M	TORRENT PHARMACEUTICALS LTD.	10/500 MG	10	TABLET	112.07	102941846.46	6.39%	6.39%	Y	11.21	11.21
74	DGSON M 10/500 MG TABLET 1	DGSON M	UNISON PHARMACEUTICALS	10/500 MG	10	TABLET	46.29	14163536.46	0.88%	0.88%	N	4.63	
75	UDAPA M 10/500 MG TABLET X	UDAPA M	USV PVT LTD	10/500 MG	10	TABLET XR	98.86	173301047.62	10.76%	10.76%	Y	9.89	9.89
76	DAPAVAS M 10/500 MG TABLET	DAPAVAS M	VASU ORGANICS PVT.LTD	10/500 MG	10	TABLET	83.57	137472.65	0.01%	0.01%	N	8.36	
77	ZINODAP M 10/500 MG TABLET	ZINODAP M	WOCKHARDT LTD	10/500 MG	15	TABLET SR	131.72	296700.96	0.02%	0.02%	N	8.78	
78	DIUTEN M 10/500 MG TABLET 1	DIUTEN M	WOCKHARDT LTD	10/500 MG	15	TABLET	119.76	479.04	0.00%	0.00%	N	7.98	
79	DAPASET M 10/500 MG TABLET	DAPASET M	WONSET HEALTH CARE PRIVATE LIMITED	10/500 MG	10	TABLET	10	142570.00	0.01%	0.01%	N	1.00	
80	DAPAFORMIN 10/500 MG TABLET	DAPAFORMIN	ZYVENTUS HEALTHCARE LTD	10/500 MG	10	TABLET	90.25	1784021.82	0.11%	0.11%	N	9.03	
81	DAPAGLYN M 10/500 MG TABLET	DAPAGLYN M	ZYDUS CADILA - ZHL	10/500 MG	15	TABLET	148.36	72071878.23	4.48%	4.48%	Y	9.89	9.89

		Rs. Per tablet											
	Worked out Retail Price	10.87	Excluding GST										

Note: In view of DPCO Amendment Vide S.O. No. 2165(E) dated 11.05.2023, Patent Holder of Dapagliflozin i.e. M/s Astra Zeneca & License holder i.e. M/s Sun Pharma and M/s Abbott Healthcare is not considered for price fixation.

Computation of Retail Price based on June 2024 Data under Para 5 of DPCO, 2013

Empagliflozin 25mg tablet	Number of Companies cosisting of Market Share of 1% & Above					5
	Sum of MAT value considered for price calculation (in Lakhs)					23,879.72
	Sum of PTR per unit considered for price calculation					205.74
	Number of Packs considered					5
	Average PTR					41.15
	Add : 16% Retailer Margin					6.58
	Retail Price (without local taxes)					47.73
	% Reduction with compared to Highest Price					15.21%

Minimum Price (Rs.)			13.50
Maximum Price (Rs.)			48.53
Average of all considered (Rs.)			41.15
Retail Price (Rs.)			47.73

[illegible]

Computation of Retail Price based on July 2024 Data under Para 5 of DPCO, 2013

Empagliflozin 10mg tablet		Number of Companies cosisting of Market Share of 1% & Above					5
		Sum of MAT value considered for price calculation (in Lakhs)					10,654.32
		Sum of PTR per unit considered for price calculation					169.99
		Number of Packs considered					5
		Average PTR					34.00
		Add : 16% Retailer Margin					5.44
		Retail Price (without local taxes)					39.44
		% Reduction with compared to Highest Price					15.11%

Minimum Price (Rs.)			11.36
Maximum Price (Rs.)			40.05
Average of all considered (Rs.)			34.00
Retail Price (Rs.)			39.44

[illegible]

Computation of Retail Price based on June 2024 Data under Para 5 of DPCO, 2013

Empagliflozin 10mg tablet	Number of Companies cosisting of Market Share of 1% & Above					5
	Sum of MAT value considered for price calculation (in Lakhs)					10,629.82
	Sum of PTR per unit considered for price calculation					169.99
	Number of Packs considered					5
	Average PTR					34.00
	Add : 16% Retailer Margin					5.44
	Retail Price (without local taxes)					39.44
	% Reduction with compared to Highest Price					15.11%

Minimum Price (Rs.)			11.36
Maximum Price (Rs.)			40.05
Average of all considered (Rs.)			34.00
Retail Price (Rs.)			39.44

[illegible]

Computation of Retail Price based on May 2024 Data under Para 5 of DPCO, 2013

Empagliflozin 25mg tablet	Number of Companies cosisting of Market Share of 1% & Above					5
	Sum of MAT value considered for price calculation (in Lakhs)					23,983.36
	Sum of PTR per unit considered for price calculation					205.74
	Number of Packs considered					5
	Average PTR					41.15
	Add : 16% Retailer Margin					6.58
	Retail Price (without local taxes)					47.73
	% Reduction with compared to Highest Price					15.21%

Minimum Price (Rs.)		13.50
Maximum Price (Rs.)		48.53
Average of all considered (Rs.)		41.15
Retail Price (Rs.)		47.73

[illegible]

Gliclazide SR Tablet 30mg	Number of Companies consisting of Market Share of 1% & Above							8
	Sum of MAT value considered for price calculation (in Lakhs)							3,687.90
	Sum of PTR per unit considered for price calculation							67.76
	Number of Packs considered							11
	Average PTR							6.16
	Add : 16% Retailer Margin							0.99
	Retail Price (without local taxes)							7.15
	% Reduction with compared to Highest Price							22.90%

Minimum Price (Rs.)			4.53
Maximum Price (Rs.)			7.99
Average of all considered (Rs.)			6.16
Retail Price (Rs.)			7.15

[illegible]

[illegible]

Computation of Retail Price based on May, 2024 Data under Para 5 of DPCO, 2013

Computation of Retail Price Based on May, 2024 Data under Para 3 of DPCO, 2019							
Gliclazide SR Tablet 60mg	Number of Companies cosisting of Market Share of 1% & Above						8
	Sum of MAT value considered for price calculation (in Lakhs)						17,456.80
	Sum of PTR per unit considered for price calculation						107.45
	Number of Packs considered						11
	Average PTR						9.77
	Add : 16% Retailer Margin						1.56
	Retail Price (without local taxes)						11.33
	% Reduction with compared to Highest Price						26.60%

Minimum Price (Rs.)			6.32
Maximum Price (Rs.)			13.31
Average of all considered (Rs.)			9.77
Retail Price (Rs.)			11.33

S.No.	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	TOTAL MAT PTR (Rs.)	1,85,05,35,818	100%	M3			
								MAT(Rs.)	SKU wise MAT %	Brandwise MAT (ignoring O% MAT)	Qualify (Y/N) Y=Yes N=No	Price per Unit (Rs.)	Price per Unit (Rs.) Considered
1	CARRYL MR 60 MG TABLET 10	CARRYL	4 CARE LIFESCIENCE PVT LTD	60 MG	10	TABLET	57.86	4230838.92	0.23%	0.23%	N	5.79	
2	GLZ 60 MG TABLET XR 15	GLZ	ALEMBIC LTD	60 MG	15	TABLET XR	163.57	95255150.20	5.15%	5.15%	Y	10.90	10.90
3	EUCLIDE 60 MG TABLET XR 10	EUCLIDE	ALKEM LABORATORIES LTD.	60 MG	10	TABLET XR	82.86	11807798.58	0.64%	0.64%	N	8.29	
4	GLUDOWN 60 MG TABLET MR 10	GLUDOWN	ALNICHE LIFE SCIENCES PVT.LTD	60 MG	10	TABLET MR	82.14	224451.10	0.01%	0.01%	N	8.21	
5	SUCRAZIDE 60 MG TABLET MR 10	SUCRAZIDE	ANTHEM BIOPHARMA PVT LTD	60 MG	10	TABLET MR	53.57	274780.67	0.01%	0.01%	N	5.36	
6	DIABEND 60 MG TABLET MR 10	DIABEND	BAL PHARMA	60 MG	10	TABLET MR	65	5158775.94	0.28%	0.28%	N	6.50	
7	RECLIDE MR 60 MG TABLET 15	RECLIDE	DR. REDDYS LABORATORIES LTD	60 MG	15	TABLET	159.29	55088386.32	2.98%	21.46%	Y	10.62	10.62
8	RECLIDE 60 MG TABLET XR 15	RECLIDE	DR. REDDYS LABORATORIES LTD	60 MG	15	TABLET XR	170.18	341890258.56	18.48%	21.46%	Y	11.35	11.35
9	GLYCOZIDE (EAST WEST) 60 MG TABL	GLYCOZIDE (EAS	EAST WEST PHARMA	60 MG	10	TABLET MR	72.52	3044462.12	0.16%	0.16%	N	7.25	
10	GLIZATO OD 60 MG TABLET 10	GLIZATO	ELBRIT LIFE SCIENCES PVT.LTD	60 MG	10	TABLET	64.29	3263103.24	0.18%	0.18%	N	6.43	
11	GZIDE 60 MG TABLET XR 10	GZIDE	ELDER PROJECTS LIMITED	60 MG	10	TABLET XR	31.8	173475.36	0.01%	0.01%	N	3.18	
12	CYBLEX 60 MG TABLET XR 15	CYBLEX	ERIS LIFESCIENCES LTD	60 MG	15	TABLET XR	156.43	87606170.70	4.73%	4.73%	Y	10.43	10.43
13	XZID 60 MG TABLET XR 10	XZID	FUSION HEALTHCARE PVT LTD	60 MG	10	TABLET XR	93.57	8826670.20	0.48%	0.48%	N	9.36	
14	GLYCITOP 60 MG TABLET MR 10	GLYCITOP	HEALING PHARMA INDIA PVT.LTD	60 MG	10	TABLET MR	17	39355.00	0.00%	0.00%	N	1.70	
15	ICOZIDE 60 MG TABLET 10	ICOZIDE	ICON LIFESCIENCES	60 MG	10	TABLET	63.57	44971.06	0.00%	0.00%	N	6.36	
16	GLIX MR 60 MG TABLET MR 10	GLIX MR	INDI PHARMA	60 MG	10	TABLET MR	104.26	3737382.91	0.20%	0.20%	N	10.43	
17	GLYCHEK MR 60 MG TABLET MR 10	GLYCHEK MR	INDOCO REMEDIES LTD	60 MG	10	TABLET MR	40.23	10862.10	0.00%	0.00%	N	4.02	
18	GLYCHEK OD 60 MG TABLET MR 10	GLYCHEK	INDOCO REMEDIES LTD	60 MG	10	TABLET MR	92.57	3711340.05	0.20%	0.20%	N	9.26	
19	NUZIDE 60 MG TABLET XL 10	NUZIDE	INTAS PHARMACEUTICALS LTD	60 MG	10	TABLET XL	57.14	2398235.34	0.13%	0.13%	N	5.71	
20	GLYCINORM OD 60 MG TABLET MR 1	GLYCINORM	IPCA LABORATORIES PVT LTD.	60 MG	15	TABLET MR	167.75	71062533.35	3.84%	3.84%	Y	11.18	11.18
21	VIDZID 60 MG TABLET XR 10	VIDZID	KEPLER HEALTH CARE	60 MG	10	TABLET XR	43.21	156463.41	0.01%	0.01%	N	4.32	
22	GLIZIHENZ 60 MG TABLET MR 10	GLIZIHENZ	LA RENON HEALTHCARE PVT.LTD	60 MG	10	TABLET MR	92.14	20530824.33	1.11%	1.11%	Y	9.21	9.21
23	LOYZIDE 60 MG TABLET XR 15	LOYZIDE	LLOYD HEALTHCARE PVT.LTD	60 MG	15	TABLET XR	103.51	4916103.94	0.27%	0.27%	N	6.90	
24	ZXR 60 MG TABLET 10	ZXR	LUPIN LTD	60 MG	10	TABLET	91.93	14262112.13	0.77%	0.77%	N	9.19	
25	GLIZID MR 60 MG TABLET MR 10	GLIZID MR	MANKIND PHARMACEUTICALS LTD.	60 MG	10	TABLET MR	77.79	68160531.48	3.68%	3.68%	Y	7.78	7.78
26	GLYKIND 60 MG TABLET XR 10	GLYKIND	MANKIND PHARMACEUTICALS LTD.	60 MG	10	TABLET XR	63.21	45936537.54	2.48%	2.48%	Y	6.32	6.32
27	NOBEGLIZ 60 MG TABLET XR 10	NOBEGLIZ	MANKIND PHARMACEUTICALS LTD.	60 MG	10	TABLET XR	47.54	14428057.22	0.78%	0.78%	N	4.75	

[illegible]

Gliclazide SR 30mg + Metformin SR 500mg Tablet	Number of Companies cosisting of Market Share of 1% & Above						11
	Sum of MAT value considered for price calculation (in Lakhs)						2,092.52
	Sum of PTR per unit considered for price calculation						69.13
	Number of Packs considered						11
	Average PTR						6.28
	Add : 16% Retailer Margin						1.00
	Retail Price (without local taxes)						7.28
	% Reduction with compared to Highest Price						23.79%

Minimum Price (Rs.)			4.36
Maximum Price (Rs.)			8.24
Average of all considered (Rs.)			6.28
Retail Price (Rs.)			7.28

[illegible]

Computation of Retail Price based on May, 2024 Data under Para 5 of DPCO, 2013

Gliclazide SR 60mg + Metformin SR 500mg Tablet	Number of Companies consisting of Market Share of 1% & Above						10
	Sum of MAT value considered for price calculation (in Lakhs)						13.030.25
	Sum of PTR per unit considered for price calculation						158.05
	Number of Packs considered						14
	Average PTR						11.29
	Add : 16% Retailer Margin						1.81
	Retail Price (without local taxes)						13.10
	% Reduction with compared to Highest Price						38.10%

Minimum Price (Rs.)			7.07
Maximum Price (Rs.)			18.24
Average of all considered (Rs.)			11.29
Retail Price (Rs.)			13.1

S.No.	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	TOTAL MAT		100%		M3		
							PTR (Rs.)	MAT(Rs.)	SKU wise MAT %	Brandwise MAT (ignoring 0% MAT)	Qualify (Y/N) Y=Yes N=No	Price per Unit (Rs.)	Price per Unit (Rs.) Considered
1	CARRYL M SR 60/500 MG TABLET	CARRYL M	4 CARE LIFESCIENCE PVT LTD	60/500 MG	10	TABLET	73.57	16642711.12	1.22%	1.22%	Y	7.36	7.36
2	ZEFORMIN 60/500 MG TABLET	ZEFORMIN	ABBOTT HEALTHCARE PVT. LTD	60/500 MG	10	TABLET XR	130.38	12752865.42	0.94%	0.94%	N	13.04	
3	GLZ MEX 60/500 MG TABLET 10	GLZ MEX	ALEMBIC LTD	60/500 MG	10	TABLET	105.5	32186671.04	2.36%	2.36%	Y	10.55	10.55
4	EUCLIDE M OD 60/500 MG TABLET	EUCLIDE M	ALKEM LABORATORIES LTD.	60/500 MG	10	TABLET	107.14	23909170.78	1.75%	1.75%	Y	10.71	10.71
5	GLUDOWN SRM 60/500 MG TABLET	GLUDOWN SRM	ALNICHE LIFE SCIENCES PVT.LTD	60/500 MG	10	TABLET	82.14	16756.56	0.00%	0.00%	N	8.21	
6	HBZIDE 60/500 MG TABLET 15	HBZIDE	ALTEUS BIOGENICS PVT.LTD.	60/500 MG	15	TABLET	84.64	359042.88	0.03%	0.03%	N	5.64	
7	DIABEND MEX 60/500 MG TABLET	DIABEND MEX	BAL PHARMA	60/500 MG	10	TABLET	113.93	4901909.43	0.36%	0.36%	N	11.39	
8	RECLIMET OD 60/500 MG TABLET	RECLIMET	DR. REDDYS LABORATORIES LTD	60/500 MG	15	TABLET	140.9	33030239.48	2.42%	21.67%	Y	9.39	9.39
9	RECLIMET 60/500 MG TABLET XR	RECLIMET	DR. REDDYS LABORATORIES LTD	60/500 MG	14	TABLET XR	255.36	262461736.32	19.25%	21.67%	Y	18.24	18.24
10	RECLIMET XR 60/500 MG TABLET	RECLIMET XR	DR. REDDYS LABORATORIES LTD	60/500 MG	15	TABLET	255.36	61019038.08	4.48%	4.48%	Y	17.02	17.02
11	GZIDE M 60/500 MG TABLET 10	GZIDE M	ELDER PROJECTS LIMITED	60/500 MG	10	TABLET	24.52	1616261.44	0.12%	0.12%	N	2.45	
12	ELDOZIDE 60/500 MG TABLET X	ELDOZIDE	EL-DORADO BIO-TECH PVT LTD	60/500 MG	10	TABLET XR	65.71	477054.60	0.03%	0.03%	N	6.57	
13	CYBLEX M 60/500 MG TABLET X	CYBLEX M	ERIS LIFESCIENCES LTD	60/500 MG	15	TABLET XR	158.86	84111702.09	6.17%	6.17%	Y	10.59	10.59
14	XZID M 60/500 MG TABLET XR	XZID M	FUSION HEALTHCARE PVT LTD	60/500 MG	10	TABLET XR	93.57	6749657.87	0.50%	0.50%	N	9.36	
15	METABEST GZ SR 60/500 MG TABLET	METABEST GZ	HBC LIFESCIENCES PVT LTD	60/500 MG	15	TABLET	116.86	357007.30	0.03%	0.03%	N	7.79	
16	GLYCHEK M OD 60/500 MG TABLET	GLYCHEK M	INDOCO REMEDIES LTD	60/500 MG	10	TABLET	97.86	12311202.14	0.90%	0.90%	N	9.79	
17	GLYCINORM M OD 60/500 MG TABLET	GLYCINORM M	IPCA LABORATORIES PVT LTD.	60/500 MG	10	TABLET	113.61	104902581.84	7.69%	7.69%	Y	11.36	11.36
18	LOYZIDE M 60/500 MG TABLET	LOYZIDE M	LLOYD HEALTHCARE PVT.LTD	60/500 MG	10	TABLET XR	132	10016556.00	0.73%	0.74%	N	13.20	
19	LOYZIDE M 60/500 MG TABLET	LOYZIDE M	LLOYD HEALTHCARE PVT.LTD	60/500 MG	15	TABLET XR	132	189211.97	0.01%	0.74%	N	8.80	
20	GLUCONORM Z 60/500 MG TABLET	GLUCONORM Z	LUPIN LTD	60/500 MG	15	TABLET XR	151.64	90492271.28	6.64%	6.64%	Y	10.11	10.11
21	GLIZID M OD 60/500 MG TABLET	GLIZID M	MANKIND PHARMACEUTICALS LTD.	60/500 MG	10	TABLET	96.8	22025256.00	1.62%	6.19%	Y	9.68	9.68
22	NOBEGLIZ M 60/500 MG TABLET	NOBEGLIZ M	MANKIND PHARMACEUTICALS LTD.	60/500 MG	10	TABLET XR	70.71	26163477.81	1.92%	1.92%	Y	7.07	7.07
23	GLIZID M XR 60/500 MG TABLET	GLIZID M	MANKIND PHARMACEUTICALS LTD.	60/500 MG	10	TABLET	96.8	62333823.20	4.57%	6.19%	Y	9.68	9.68
24	GLYKIND-M XR 60/500 MG TABLET	GLYKIND-M	MANKIND PHARMACEUTICALS LTD.	60/500 MG	10	TABLET	80	1849040.00	0.14%	0.14%	N	8.00	
25	DIANORM M OD 60/500 MG TABLET	DIANORM M	MICRO LABS LTD	60/500 MG	10	TABLET	105	20440035.00	1.50%	1.50%	Y	10.50	10.50
26	MCLAZIDE M 60/500 MG TABLET	MCLAZIDE M	MITOCH PHARMA PVT LTD	60/500 MG	10	TABLET XR	48	1036272.00	0.08%	0.08%	N	4.80	
27	DIAMICRON MEX 60/500 MG TABLET	DIAMICRON MEX	SERDIA PHARMACEUTICALS (INDIA) PVT. LTD	60/500 MG	14	TABLET XR	221.04	463306029.12	33.98%	33.98%	Y	15.79	15.79

